Skip to main content
Caplight Logo









Vivatides Therapeutics

Vivatides Therapeutics

Private
Woburn, MassachusettsHealthcare & Life Scienceshttps://www.prnewswire.com/

Last Round

Series A

Apr 10, 2026

Total Funding Raised

$64M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Vivatides Therapeutics is a biotechnology company that develops extrahepatic RNA-targeting therapeutics using a proprietary delivery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

peptide therapeuticsdrug discoverybiotechnologyoligonucleotide therapeuticssiRNAASOdrug deliverybiopharmapreclinical researchligand conjugationdrug developmenttherapeutic pipelinebiotech startupdrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivatides Therapeutics Comparables

Compare Vivatides Therapeutics with similar companies based on industry and business-model similarity.

Vivatides Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nosis Bio
88%
Rona Therapeutics
79%
Procavea Biotech
78%

Vivatides Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 10, 2026
SeedSep 1, 2025

Key People

Founding team and executive leadership

Alexandra Petrie

PA To CEO

Executive Team

Virginia Spagnuolo

Principal Chief Executive Officer

Executive Team

Dan Ye

CFO Director Of Business Development

Executive Team

Zhiwei REN

CFO - APAC Region At Cision PR Newswire

Executive Team

Vivatides Therapeutics Investors

Notable investors and investment history

Vivatides Therapeutics investors
InvestorRounds
HighLight CapitalSeries A
Highlight CapitalSeries A
TF CapitalSeries A
Qiming Venture PartnersSeed, Series A
Apricot CapitalSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2026

    Raised $54M in Series A funding.

  • Sep 1, 2025

    $10M round led by Apricot Capital

Vivatides Therapeutics Filings

Explore SEC and related filing metadata, where available.

Vivatides Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Vivatides Therapeutics's valuation, stock price, and market status.

Is Vivatides Therapeutics a public or private company?

Vivatides Therapeutics is a private company.

What is the current stock price of Vivatides Therapeutics?

Vivatides Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Vivatides Therapeutics worth (valuation)?

Valuation information for Vivatides Therapeutics is not publicly available.

Can I buy Vivatides Therapeutics stock?

Vivatides Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Vivatides Therapeutics's last funding round?

Vivatides Therapeutics's most recent funding round was Series A on April 10, 2026.

Who are the main investors in Vivatides Therapeutics?

Key investors in Vivatides Therapeutics include Qiming Venture Partners.

Will Vivatides Therapeutics IPO soon?

No public IPO plans have been announced for Vivatides Therapeutics.

How can I track Vivatides Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vivatides Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWoburn, Massachusetts
Employee Range1,113
Year Founded2025
Last FundingApr 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?